Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy

Pathophysiological cardiac hypertrophy is one of the most common causes of heart failure. Epoxyeicosatrienoic acids, hydrolyzed and degraded by soluble epoxide hydrolase (sEH), can function as endothelium-derived hyperpolarizing factors to induce dilation of coronary arteries and thus are cardioprotective. In this study, we investigated the role of sEH in two rodent models of angiotensin II (Ang II)-induced cardiac hypertrophy. The protein level of sEH was elevated in the heart of both spontaneously hypertensive rats and Ang II-infused Wistar rats. Blocking the Ang II type 1 receptor with losartan could abolish this induction. Administration of a potent sEH inhibitor (sEHI) prevented the pathogenesis of the Ang II-induced hypertrophy, as demonstrated by decreased left-ventricular hypertrophy assessed by echocardiography, reduced cardiomyocyte size, and attenuated expression of hypertrophy markers, including atrial natriuretic factor and β-myosin heavy chain. Because sEH elevation was not observed in exercise- or norepinephrine-induced hypertrophy, the sEH induction was closely associated with Ang II-induced hypertrophy. In vitro, Ang II upregulated sEH and hypertrophy markers in neonatal cardiomyocytes isolated from rat and mouse. Expression of these marker genes was elevated with adenovirus-mediated sEH overexpression but decreased with sEHI treatment. These results were supported by studies in neonatal cardiomyocytes from sEH−/− mice. Our results suggest that sEH is specifically upregulated by Ang II, which directly mediates Ang II-induced cardiac hypertrophy. Thus, pharmacological inhibition of sEH would be a useful approach to prevent and treat Ang II-induced cardiac hypertrophy.

[1]  B. Hammock,et al.  The soluble epoxide hydrolase as a pharmaceutical target for hypertension. , 2007, Journal of cardiovascular pharmacology.

[2]  W. Bao,et al.  Effects of p38 MAPK Inhibitor on Angiotensin II-Dependent Hypertension, Organ Damage, and Superoxide Anion Production , 2007, Journal of cardiovascular pharmacology.

[3]  Yi Fu,et al.  Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo , 2007, Proceedings of the National Academy of Sciences.

[4]  B. Hammock,et al.  Compensatory Mechanism for Homeostatic Blood Pressure Regulation in Ephx2 Gene-disrupted Mice* , 2007, Journal of Biological Chemistry.

[5]  Yunyu Zhang,et al.  Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling in dilated and hypertrophic cardiomyopathy , 2007, Proceedings of the National Academy of Sciences.

[6]  B. Hammock,et al.  Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors , 2006, Proceedings of the National Academy of Sciences.

[7]  A. Terzic,et al.  Protection conferred by myocardial ATP‐sensitive K+ channels in pressure overload‐induced congestive heart failure revealed in KCNJ11 Kir6.2‐null mutant , 2006, The Journal of physiology.

[8]  Paul D. Jones,et al.  Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. , 2006, Bioorganic & medicinal chemistry letters.

[9]  J. Falck,et al.  Role of Soluble Epoxide Hydrolase in Postischemic Recovery of Heart Contractile Function , 2006, Circulation research.

[10]  R. DePinho,et al.  Class IA Phosphoinositide 3-Kinase Regulates Heart Size and Physiological Cardiac Hypertrophy , 2005, Molecular and Cellular Biology.

[11]  B. Hammock,et al.  An Orally Active Epoxide Hydrolase Inhibitor Lowers Blood Pressure and Provides Renal Protection in Salt-Sensitive Hypertension , 2005, Hypertension.

[12]  J. Daut,et al.  K(ATP) channels and preconditioning: a re-examination of the role of mitochondrial K(ATP) channels and an overview of alternative mechanisms. , 2005, Journal of molecular and cellular cardiology.

[13]  G. Shull,et al.  The effects of intracellular Ca2+ on cardiac K+ channel expression and activity: novel insights from genetically altered mice , 2005, The Journal of physiology.

[14]  B. Hammock,et al.  Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. , 2004, Journal of medicinal chemistry.

[15]  A. Shah,et al.  Contrasting Roles of NADPH Oxidase Isoforms in Pressure-Overload Versus Angiotensin II–Induced Cardiac Hypertrophy , 2003, Circulation research.

[16]  M. Hori,et al.  Activation of Adenosine A1 Receptor Attenuates Cardiac Hypertrophy and Prevents Heart Failure in Murine Left Ventricular Pressure-Overload Model , 2003, Circulation research.

[17]  G. Gross,et al.  KATP channels and myocardial preconditioning: an update. , 2003, American journal of physiology. Heart and circulatory physiology.

[18]  Michael D. Schneider,et al.  Sizing up the heart: development redux in disease. , 2003, Genes & development.

[19]  Nathan R. McElroy,et al.  QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds. , 2003, Journal of medicinal chemistry.

[20]  Yongge Liu,et al.  Cytoprotective Role of Ca2+- Activated K+ Channels in the Cardiac Inner Mitochondrial Membrane , 2002, Science.

[21]  C. Wheelock,et al.  Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. , 2002, Biochemical pharmacology.

[22]  B. Hammock,et al.  Soluble Epoxide Hydrolase Inhibition Lowers Arterial Blood Pressure in Angiotensin II Hypertension , 2002, Hypertension.

[23]  H. Piper,et al.  Transcription activator protein 1 (AP‐1) mediates NO‐induced apoptosis of adult cardiomyocytes , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  H. Piper,et al.  Redox‐sensitve intermediates mediate angiotensin II‐induced p38 MAP kinase activation, AP‐1 binding activity, and TGF‐β expression in adult ventricular cardiomyocytes , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  Lan Mao,et al.  Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. , 2001, Journal of the American College of Cardiology.

[26]  M. D. de Bold,et al.  The physiological and pathophysiological modulation of the endocrine function of the heart. , 2001, Canadian journal of physiology and pharmacology.

[27]  S. Liu,et al.  Reactive oxygen species modulate angiotensin II-induced beta-myosin heavy chain gene expression via Ras/Raf/extracellular signal-regulated kinase pathway in neonatal rat cardiomyocytes. , 2001, Biochemical and biophysical research communications.

[28]  F. Luft,et al.  Mineralocorticoid Receptor Affects AP-1 and Nuclear Factor-&kgr;B Activation in Angiotensin II–Induced Cardiac Injury , 2001, Hypertension.

[29]  B D Hammock,et al.  Soluble Epoxide Hydrolase Regulates Hydrolysis of Vasoactive Epoxyeicosatrienoic Acids , 2000, Circulation research.

[30]  Shokei Kim,et al.  Important Role of Angiotensin II-Mediated c-Jun NH2-Terminal Kinase Activation in Cardiac Hypertrophy in Hypertensive Rats , 2000, Hypertension.

[31]  J. Sadoshima,et al.  Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. , 2000, The Biochemical journal.

[32]  J. Molkentin,et al.  Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  B D Hammock,et al.  Potent urea and carbamate inhibitors of soluble epoxide hydrolases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Fryer,et al.  Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning. , 1999, Circulation research.

[35]  J. Borecký,et al.  Ca2+-activated K channel of the BK-type in the inner mitochondrial membrane of a human glioma cell line. , 1999, Biochemical and biophysical research communications.

[36]  Shokei Kim,et al.  Differential activation of cardiac c-jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension. , 1998, Circulation research.

[37]  Yongge Liu,et al.  Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? , 1998, Circulation.

[38]  H. Matsubara,et al.  Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. , 1998, Circulation.

[39]  M. Horie,et al.  Functional compartmentalization of ATP is involved in angiotensin II-mediated closure of cardiac ATP-sensitive K+ channels. , 1997, Circulation.

[40]  K. Tomer,et al.  Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. , 1996, Archives of biochemistry and biophysics.

[41]  A. Katz.  The cardiomyopathy of overload: an unnatural growth response. , 1995, European heart journal.

[42]  C. Gohlke-Bärwolf,et al.  Prevention of bacterial endocarditis in Germany. , 1995, European heart journal.

[43]  E. Morkin.  Regulation of Myosin Heavy Chain Genes in the Heart , 1993, Circulation.

[44]  B. Hammock,et al.  Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2. , 2008, Biochimica et biophysica acta.

[45]  C. Morisseau,et al.  Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble expoxide hydrolase , 2007, Cell Biochemistry and Biophysics.

[46]  Qin M. Chen,et al.  Distinct roles of p42/p44ERK and p38 MAPK in oxidant-induced AP-1 activation and cardiomyocyte hypertrophy , 2007, Cardiovascular Toxicology.

[47]  Xiang Fang,et al.  Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. , 2004, Progress in lipid research.

[48]  B. O’Rourke,et al.  Evidence for Mitochondrial K Channels and Their Role in Cardioprotection , 2004 .

[49]  Y. Zou,et al.  Angiotensin II stimulates c-Jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. , 1997, Circulation research.